厄洛替尼一线治疗老年晚期非小细胞肺癌临床观察  

Clinical Observation of Erlotinib as First Line Treatment for Elderly Patients with Advanced NSCLC

作　　者：樊卫飞[1] 王峻[1] 孟丽娟[1] 刘福银[1] 蒲骁麟[1] 杨民[1] 

机构地区：[1]江苏省老年医学研究所,江苏南京210024

出　　处：《肿瘤学杂志》2012年第3期174-177,共4页Journal of Chinese Oncology

摘　　要：[目的]比较厄洛替尼靶向与紫杉醇单药一线治疗老年晚期非小细胞肺癌(NSCLC)患者的疗效和不良反应。[方法]经病理确诊的老年晚期NSCLC患者62例,厄洛替尼治疗组32例:口服厄洛替尼150mg,1次/d;紫杉醇化疗组30例:紫杉醇75mg/m2,d1、8,静脉滴注,21d为1个周期,2个周期后评价疗效。[结果]厄洛替尼治疗组和紫杉醇化疗组近期有效率(RR)分别为28.1%、36.7%,肿瘤控制率(TGCR)分别为71.9%、66.7%,差异无统计学意义(P>0.05);中位无疾病进展时间(PFS)分别为5.6个月、5.1个月;中位生存期(OS)分别为9.0个月、8.0个月。两组不良反应均可耐受,厄洛替尼治疗组骨髓抑制发生率明显低于紫杉醇化疗组(P<0.05),厄洛替尼治疗组皮疹及腹泻发生率明显较高(P<0.05)。[结论]老年晚期NSCLC患者可从厄洛替尼靶向治疗中获益,不良反应轻微。[Purpose] To compare the efficacy and toxicity of erlotinib and pacilitaxel in the first-line treatment for elderly patients with advanced non-small cell lung cancer.[Methods]Sixty-two elderly cases with histologically or cytologically proven advanced non-small cell lung cancer were divided into two gourps.Thirty-two patients in erlotinib group at a dose of 150mg/d p.o.Thirty patients underwent pacilitaxel intravenously injection at a dose of 75mg/m2.The efficacy was evaluated after 2 cycles（every 21 days as a cycle）.[Results]The response rates（RR） of erlotinib and pacilitaxel group were 28.1% and 36.7%,respectively;the tumor growth control rates（TGCR） of the 2 groups,71.9% and 66.7%,respectively,with no significant difference（P0.05）;median progression-free survival（PFS）,5.6 months and 5.1 months,median overall survival（OS）,9 months and 8 months,respectively.Meanwhile,the toxicity was tolerable in both groups.The occurrence of arrest of bone marrow in erlotinib group was significantly lower than that in paclitaxel group（P0.05）,while the occurrence of rush and diarrhea in erlotinib group was obviously higher than that in the other group（P0.05）.[Conclusion] Elderly patients with advanced non-small cell lung cancer can benefit from target treatment of erlotinib with mild toxicity.

关 键 词：厄洛替尼 紫杉醇 肺肿瘤 老年人 一线治疗 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]